Table:
|  | June 30, |  |
| --- | --- | --- |
|  | 2019 | 2018 |
| Deferred tax assets |  |  |
| Non-capital loss carryforwards | $161,119 | $129,436 |
| Capital loss carryforwards | 155 | 417 |
| Undeducted scientific research and development expenses | 137,253 | 123,114 |
| Depreciation and amortization | 683,777 | 829,369 |
| Restructuring costs and other reserves | 17,845 | 17,202 |
| Deferred revenue | 53,254 | 62,726 |
| Other | 59,584 | 57,461 |
| Total deferred tax asset | $1,112,987 | $1,219,725 |
| Valuation Allowance | $(77,328) | $(80,924) |
| Deferred tax liabilities |  |  |
| Scientific research and development tax credits | $(14,482) | $(13,342) |
| Other | (72,599) | (82,668) |
| Deferred tax liabilities | $(87,081) | $(96,010) |
| Net deferred tax asset | $948,578 | $1,042,791 |
| Comprised of: |  |  |
| Long-term assets | 1,004,450 | 1,122,729 |
| Long-term liabilities | (55,872) | (79,938) |
|  | $948,578 | $1,042,791 |
Paragraphs:
The primary components of the deferred tax assets and liabilities are as follows, for the periods indicated below:
We believe that sufficient uncertainty exists regarding the realization of certain deferred tax assets that a valuation allowance is required. We continue to evaluate our taxable position quarterly and consider factors by taxing jurisdiction, including but not limited to factors such as estimated taxable income, any historical experience of losses for tax purposes and the future growth of OpenText.
Question:
What does the table show?